A multidisciplinary consortium led by Danish biotech company PreTT ApS has received a DKK 31.2 million (€4 million) investment from Innovation Fund Denmark for the PRE-BREACH project. The project aims to develop a groundbreaking radiotherapy capable of crossing the blood-brain barrier to treat glioblastoma, one of the most aggressive and deadly forms of brain cancer. Glioblastoma remains one of the most lethal cancers, with 75–80% of patients dying within two years of diagnosis. Its location in the brain severely limits treatment options such as surgery and external radiation, while the blood-brain barrier prevents most therapies from reaching the tumour. Engineering how alpha radiation reaches its destination to fight cancer The PRE-BREACH project brings together three advanced technologies in a single therapeutic platform designed to deliver radiation with high precision: A shuttle mechanism: a specially designed antibody that actively crosses the otherwise impenetrable blood-brain b

PreTT ApS (“PreTT”), a Copenhagen-based company developing a pioneering pretargeted radioligand therapy (RLT) platform, today announced a CEO transition to support the company’s strong momentum and next phase of growth. By mutual agreement with the Board of Directors, Mr. Francesco Sergi‑Lindell has stepped down from his role as Chief Executive Officer and has departed the company. The Board thanks Mr. Sergi‑Lindell for his leadership and his important contributions in establishing PreTT’s foundation and early progress. ​Effective now, Dr. Natalia Herrero Alvarez, previously R&D Director, has been appointed Chief Executive Officer. Dr. Herrero Alvarez has been at the center of PreTT’s scientific strategy and pipeline, and her appointment reflects the company’s confidence in its technology, trajectory, and long‑term ambitions. ​“PreTT is entering a very exciting phase, with strong scientific momentum and a clear path to value‑creating milestones,” said Hans Schambye, M.D., Ph.D., Chairm